MedTrace Logo

Intravenous CAngrelor in High-bleeding Risk Patients Undergoing percutaneouS Coronary Intervention (ICARUS) Registry

NCT05505591 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2022-08-18

No results posted yet for this study

Summary

The study will investigate the prevalence of high bleeding risk (HBR) features and will compare the clinical outcomes of HBR and non-HBR patients among those undergoing percutaneous coronary intervention and receiving cangrelor infusion.

Conditions

Interventions

DRUG

Cangrelor

Cangrelor administration during percutaneous coronary intervention for both chronic or acute coronary syndromes

Sponsors & Collaborators

  • University of Campania Luigi Vanvitelli

    collaborator OTHER

  • Universita degli Studi di Genova

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-06
Primary Completion
2022-10-31
Completion
2022-10-31
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05505591 on ClinicalTrials.gov